The Power and Pitfalls of Omics: George Davey Smith’s storming talk at ME/CFS conference
Read about the talk that stole the show at a recent ME/CFS conference in Simon McGrath's two-part blog.
Discuss the article on the Forums.

Generic valcyte in India article

Discussion in 'Other Health News and Research' started by heapsreal, Dec 12, 2011.

  1. heapsreal

    heapsreal iherb 10% discount code OPA989,

    Messages:
    8,831
    Likes:
    8,096
    australia (brisbane)
    Victory for access to medicines as Valganciclovir patent is rejected in India

    06.05.10










    5 May 2010, Geneva/New Delhi - International medical humanitarian organisation Mdecins Sans Frontires welcomes the decision by the Indian Patent Office to reject the product patent it had previously granted to pharmaceutical company Roche for the drug valganciclovir.

    Valganciclovir is primarily used as treatment and prevention of an infection caused by cytomegalovirus (CMV) in organ transplant patients, a highly lucrative market which Roche has sought to defend by patenting the medicine. But CMV also affects people living with HIV, and if left untreated, can cause blindness and death.

    Roche was attempting to patent a new form of a drug that was really invented in the 1980s, said Leena Menghaney, Project Manager of the Mdecins Sans Frontires Campaign for Access to Essential Medicines in India. This decision shows that Section 3(d) of Indias Patents Act, which prevents companies from filing unjustified patents, is working. Equally importantly, the Patent Office also found separately that the patent claims were obvious and therefore not patentable.

    Through this decision, the Indian Patent Office has also confirmed the right of patients groups to oppose a patent after it has been granted, a matter on which Roche claimed there was ambiguity. This follows a similar recognition in 2002 in Thailand of patients as persons interested in the outcome of a patent application.

    For people living with HIV/AIDS in developing countries, accessing valganciclovir at Roche prices was difficult, said Loon Gangte of the Delhi Network of Positive People (DNP+), one of the patient groups that filed an opposition to the patent. The decision will provide much needed relief as it secures the way for generic competition, which is the most effective and sustainable way of bringing drug prices down.

    To date, the price of valganciclovir is prohibitively expensive Roche markets the drugs for up to US$8,500 for a four-month treatment course in high-income countries. In India, the Roche price for a standard protocol is approximately $5,950. In December 2006, Mdecins Sans Frontires approached Roche for a discount, but even the discounted price was so high that some Mdecins Sans Frontires AIDS projects opted out of providing this treatment for CMV.

    This is one victory for access to medicines, but we have to be careful not to lose an even bigger fight, said Leena Menghaney. India is currently negotiating a free trade agreement with the EU. If the country agrees to introduce stricter intellectual property provisions such as data exclusivity as a part of these talks, this would allow companies to create new monopolies on medicines even where patents have been rejected as in the present case.

    http://www.msf.org.au/media-room/pr...lganciclovir-patent-is-rejected-in-india.html
     
  2. heapsreal

    heapsreal iherb 10% discount code OPA989,

    Messages:
    8,831
    Likes:
    8,096
    australia (brisbane)
    So the Indians are realising big pharma are ripping people off and the many more people that need these medicines cant afford it.
    Good on em!
    Still expensive but atleast its in reach.

    cheers!!!
     

See more popular forum discussions.

Share This Page